Literature DB >> 23155124

Clinical specificity of the enzyme immunoassay test for coccidioidomycosis varies according to the reason for its performance.

Janis E Blair1, Neil Mendoza, Shannon Force, Yu-Hui H Chang, Thomas E Grys.   

Abstract

The diagnosis of coccidioidomycosis relies heavily on serologic test results in addition to clinical history, physical examination, and radiographic findings. Use of the enzyme immunoassay (EIA) has increased because it is rapidly performed and does not require referral to a reference laboratory, as do complement fixation and immunodiffusion tests. However, interpretation of immunoglobulin M (IgM) reactivity by EIA in the absence of immunoglobulin G (IgG) reactivity has been problematic. We conducted a retrospective medical record review of all patients with such IgM reactivity at our institution to identify situations where the finding was more likely to be clinically specific for coccidioidal infection. From 1 January 2004 through 31 December 2008, a total of 1,117 patients had positive EIA coccidioidal serology or EIA IgM-only reactivity; of these, 102 patients (9%) had EIA IgM-only reactivity. Among the 102 patients with EIA IgM-only reactivity, 60 were tested to evaluate symptomatic illness, 13 for follow-up of previously abnormal serology, and 29 for screening purposes. Of the 102 patients, 80 (78%) had positive serologic findings by other methods or had positive culture or histology. Fifty-four (90%) of the 60 patients whose serology was performed to evaluate symptomatic illness had coccidioidal infection, whereas 13 (45%) of 29 patients whose serology was performed for screening purposes had coccidioidal infection. Of the 102 patients with isolated IgM reactivity by EIA, 12 later seroconverted to IgG and IgM reactivity. The use of EIA for screening in 29 asymptomatic persons was associated with unconfirmable results in 13 (45%). Although the majority of patients in our study with isolated IgM reactivity by EIA had probable or confirmed coccidioidomycosis, this result must be interpreted with caution for asymptomatic patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23155124      PMCID: PMC3535779          DOI: 10.1128/CVI.00531-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  15 in total

1.  Detection of coccidioidal antibodies by 33-kDa spherule antigen, Coccidioides EIA, and standard serologic tests in sera from patients evaluated for coccidioidomycosis.

Authors:  M A Wieden; L L Lundergan; J Blum; K L Delgado; R Coolbaugh; R Howard; T Peng; E Pugh; N Reis; J Theis; J N Galgiani
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

2.  Early treatment with fluconazole may abrogate the development of IgG antibodies in coccidioidomycosis.

Authors:  George R Thompson; Jennine M Lunetta; Suzanne M Johnson; Sandra Taylor; Derek Bays; Stuart H Cohen; Demosthenes Pappagianis
Journal:  Clin Infect Dis       Date:  2011-09       Impact factor: 9.079

3.  Comparison of commercially available enzyme immunoassay with traditional serological tests for detection of antibodies to Coccidioides immitis.

Authors:  T B Martins; T D Jaskowski; C L Mouritsen; H R Hill
Journal:  J Clin Microbiol       Date:  1995-04       Impact factor: 5.948

4.  Comparative evaluation of commercial Premier EIA and microimmunodiffusion and complement fixation tests for Coccidioides immitis antibodies.

Authors:  L Kaufman; A S Sekhon; N Moledina; M Jalbert; D Pappagianis
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

5.  Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts.

Authors:  Janis E Blair; Brandon Coakley; Ana C Santelli; Joseph G Hentz; Nancy L Wengenack
Journal:  Mycopathologia       Date:  2006-11       Impact factor: 2.574

6.  Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies.

Authors:  Nancy F Crum; Edith R Lederman; Christopher M Stafford; J Scott Parrish; Mark R Wallace
Journal:  Medicine (Baltimore)       Date:  2004-05       Impact factor: 1.889

Review 7.  Pulmonary coccidioidomycosis.

Authors:  P Batra
Journal:  J Thorac Imaging       Date:  1992-09       Impact factor: 3.000

8.  Coccidioidomycosis as a common cause of community-acquired pneumonia.

Authors:  Lisa Valdivia; David Nix; Mark Wright; Elizabeth Lindberg; Timothy Fagan; Donald Lieberman; T'Prien Stoffer; Neil M Ampel; John N Galgiani
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

9.  Significance of isolated positive IgM serologic results by enzyme immunoassay for coccidioidomycosis.

Authors:  Janis E Blair; Jeremiah T Currier
Journal:  Mycopathologia       Date:  2008-06-04       Impact factor: 3.785

10.  Testing for coccidioidomycosis among patients with community-acquired pneumonia.

Authors:  Douglas C Chang; Shoana Anderson; Kathleen Wannemuehler; David M Engelthaler; Laura Erhart; Rebecca H Sunenshine; Lauren A Burwell; Benjamin J Park
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

View more
  12 in total

1.  Evaluation of the Specificity of Two Enzyme Immunoassays for Coccidioidomycosis by Using Sera from a Region of Endemicity and a Region of Nonendemicity.

Authors:  Mark D Lindsley; YoonJi Ahn; Orion McCotter; Lalitha Gade; Steven F Hurst; Mary E Brandt; Benjamin J Park; Anastasia P Litvintseva
Journal:  Clin Vaccine Immunol       Date:  2015-08-05

Review 2.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

Review 3.  Dust devil: the life and times of the fungus that causes valley Fever.

Authors:  Eric R G Lewis; Jolene R Bowers; Bridget M Barker
Journal:  PLoS Pathog       Date:  2015-05-14       Impact factor: 6.823

4.  Coccidioidomycosis in a State Where It Is Not Known To Be Endemic - Missouri, 2004-2013.

Authors:  George Turabelidze; Ravi K Aggu-Sher; Ehsan Jahanpour; C Jon Hinkle
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-19       Impact factor: 17.586

5.  Coccidioidomycosis: epidemiology.

Authors:  Jennifer Brown; Kaitlin Benedict; Benjamin J Park; George R Thompson
Journal:  Clin Epidemiol       Date:  2013-06-25       Impact factor: 4.790

6.  Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.

Authors:  Janis E Blair; Yu-Hui H Chang; Meng-Ru Cheng; Laszlo T Vaszar; Holenarasipur R Vikram; Robert Orenstein; Shimon Kusne; Stanford Ho; Maria T Seville; James M Parish
Journal:  Emerg Infect Dis       Date:  2014-06       Impact factor: 6.883

7.  Distance from construction site and risk for coccidioidomycosis, Arizona, USA.

Authors:  Janis E Blair; Yu-Hui H Chang; Yvette Ruiz; Stacy Duffy; Beth E Heinrich; Douglas F Lake
Journal:  Emerg Infect Dis       Date:  2014-09       Impact factor: 6.883

8.  Top Questions in the Diagnosis and Treatment of Coccidioidomycosis.

Authors:  Fariba M Donovan; Tirdad T Zangeneh; Joshua Malo; John N Galgiani
Journal:  Open Forum Infect Dis       Date:  2017-09-12       Impact factor: 3.835

9.  Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Chadi A Hage; Eva M Carmona; Oleg Epelbaum; Scott E Evans; Luke M Gabe; Qusay Haydour; Kenneth S Knox; Jay K Kolls; M Hassan Murad; Nancy L Wengenack; Andrew H Limper
Journal:  Am J Respir Crit Care Med       Date:  2019-09-01       Impact factor: 21.405

Review 10.  Coccidioidomycosis: Changing Concepts and Knowledge Gaps.

Authors:  Neil M Ampel
Journal:  J Fungi (Basel)       Date:  2020-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.